Your browser doesn't support javascript.
Vaccinations in Children and Adolescents Treated With Immune-Modifying Biologics: Update and Current Developments.
Martire, Baldassarre; Ottaviano, Giorgio; Sangerardi, Maria; Sgrulletti, Mayla; Chini, Loredana; Dellepiane, Rosa Maria; Montin, Davide; Rizzo, Caterina; Pignata, Claudio; Marseglia, Gian Luigi; Moschese, Viviana.
  • Martire B; Pediatrics and Neonatology Unit, Maternal-Infant Department, Monsignor A. R. Dimiccoli Hospital, Barletta, Italy. Electronic address: baldo.martire@gmail.com.
  • Ottaviano G; Molecular and Cellular Immunology Unit, Great Ormond Street Institute of Child Health, University College of London, London, UK.
  • Sangerardi M; Department of Pediatrics and Emergency, Pediatric Hospital, Policlinico - University of Bari, Bari, Italy.
  • Sgrulletti M; Pediatric Immunopathology and Allergology Unit, University of Rome, Tor Vergata, Policlinico Tor Vergata, Rome, Italy.
  • Chini L; Pediatric Immunopathology and Allergology Unit, University of Rome, Tor Vergata, Policlinico Tor Vergata, Rome, Italy.
  • Dellepiane RM; Pediatric Intermediate Care Unit, Scientific Institute for Research, Hospitalization and Healthcare Foundation (IRCSS); Ca Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Montin D; Department of Public Health and Pediatrics, Regina Margherita Children Hospital, University of Turin, Turin, Italy.
  • Rizzo C; Innovation and Clinical Pathways Unit, Bambino Gesù Children Hospital, IRCCS, Rome, Italy.
  • Pignata C; Department of Translational Medical Sciences-Section of Pediatrics, Federico II University of Naples, Naples, Italy.
  • Marseglia GL; Department of Pediatrics, IRCCS Foundation, Policlinico San Matteo, University of Pavia, Pavia, Italy.
  • Moschese V; Pediatric Immunopathology and Allergology Unit, University of Rome, Tor Vergata, Policlinico Tor Vergata, Rome, Italy.
J Allergy Clin Immunol Pract ; 10(6): 1485-1496, 2022 06.
Article in English | MEDLINE | ID: covidwho-2159175
ABSTRACT
Treatment with immune-modifying biologics has positively impacted disease control and quality of life in many patients with immune-mediated disorders. However, the higher susceptibility to common and opportunistic pathogens is of concern. Thus, immunization strategies to control vaccine-preventable diseases represent a critical issue in this population. However, limited data exist on the safety, immunogenicity, and efficacy of available vaccines in patients on biologics, particularly in children. Here, according to published literature and real-life experience and practice, we report the interim indications of the Italian Society of Pediatric Allergology and Immunology (SIAIP) Vaccine Committee and of the Italian Primary Immunodeficiency Network (IPINet) Centers on immunization of children and adolescents receiving biologics. Our aim is to provide a practical guidance for the clinician to ensure optimal protection for patients and the community.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Biological Products / Vaccines Topics: Vaccines Limits: Adolescent / Child / Humans Language: English Journal: J Allergy Clin Immunol Pract Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Biological Products / Vaccines Topics: Vaccines Limits: Adolescent / Child / Humans Language: English Journal: J Allergy Clin Immunol Pract Year: 2022 Document Type: Article